VIR Vir Biotechnology, Inc.

8-K Current Report

Filed: February 26, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Vir Biotechnology, Inc. (VIR) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 1.01: Entry into a Material Definitive Agreement

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Vir Bio priced public offering of 17,647,059 shares at $8.50/share, closing Feb 27, 2026
• Net proceeds ~$141.1M base; up to ~$162.3M if underwriters exercise full 2,647,058-share overallotment option

+2 more insights

Other Vir Biotechnology, Inc. 8-K Filings

8-K Mar 4, 2026

8-K Mar 2, 2026

8-K Feb 23, 2026

Get deeper insights on Vir Biotechnology, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.